Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.35 |
| ▸ | PDE2A | O00408 | 2/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 3/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | IDH1 | O75874 | 2/20 | 0.30 |
| ▸ | CDK4 | P11802 | 2/20 | 0.30 |
| ▸ | CCND1 | P24385 | 2/20 | 0.30 |
| ▸ | CDK7 | P50613 | 2/20 | 0.30 |
| ▸ | CCNH | P51946 | 2/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL863998 | 0.88 | KCNN3 (0.40) | PIK3CDPIK3R1KCNN3PDE2ACCNT1 | |
| SCHEMBL2114088 | 0.88 | KCNN3 (0.40) | PIK3CDPIK3R1KCNN3PDE2ACCNT1 | |
| SCHEMBL2115344 | 0.84 | OPRK1 (0.38) | PIK3CDPIK3R1KCNN3CCNT1CDK9 | |
| SCHEMBL2115342 | 0.84 | OPRK1 (0.38) | PIK3CDPIK3R1KCNN3CCNT1CDK9 | |
| SCHEMBL863800 | 0.82 | KCNN3 (0.39) | PIK3CDPIK3R1KCNN3 | |
| SCHEMBL2116488 | 0.81 | IDH1 (0.43) | PIK3CDPIK3R1IDH1 | |
| SCHEMBL2115816 | 0.81 | IDH1 (0.38) | PIK3CDPIK3R1KCNN3IDH1 | |
| SCHEMBL865639 | 0.81 | KDM4E (0.37) | PIK3CDPIK3R1KCNN3 | |
| SCHEMBL865638 | 0.81 | KDM4E (0.37) | PIK3CDPIK3R1KCNN3 | |
| SCHEMBL2114085 | 0.80 | OPRK1 (0.34) | PIK3CDPIK3R1CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513284-B2 | Fused pyridine and pyrazine derivatives as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077815-A1 | Fused Pyridine And Pyrazine Derivatives As Kinase Inhibitors | PDPK1, PDXK, PIK3CA | PIK3CD 14/4885PIK3R1 133/4885KCNN3 1241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.